18. Future leads
Sources for this sheet (31)
- Ontunisertib — NOV-ERA phase 2b placebo-controlled trial in fibrostenosing Crohn's disease, 320 patients planned, started 30 October 2026 (NCT07683325)
- PALI-2108 — Open-label phase 1b in 6 patients with fibrostenosing Crohn's disease, 14 days of treatment (NCT07428096)
- PALI-2108 — Phase 2 placebo-controlled trial in ulcerative colitis, 204 patients planned, started 28 August 2026 (NCT07845487)
- MBF-118 — Phase 2a trial in Crohn's disease, 10 patients, completed 10 September 2024 (NCT05940558)
- Duvakitug — Sanofi and Teva — RELIEVE UCCD phase 2b maintenance results over 44 weeks (17 February 2026)
- ABBV-466 (Skyrizi + trosunilimab) — AbbVie — phase 2a TARGET-CD presented at UEG Week, 300 patients, open-label (19 October 2026)
- SPY001, SPY002, SPY003 — SKYLINE-UC phase 2 platform trial, three antibodies alone then in combination, 645 patients planned, primary completion June 2027 (NCT07012395)
- SPY001, SPY002, SPY003 — Spyre Therapeutics — phase 1 results: about 75-day half-life, supporting quarterly or less frequent dosing (17 June 2025)
- MORF-057 — EMERALD-2 phase 2b trial in ulcerative colitis, 280 patients, completed 28 November 2024 (NCT05611671)
- MORF-057 — GARNET phase 2 trial in Crohn's disease, 385 patients, primary completion September 2028 (NCT06226883)
- MORF-057 — TOPAZ-UC phase 2 trial, combined with mirikizumab (Omvoh), 252 patients, primary completion May 2027 (NCT07186101)
- Emvistegrast — Gilead — phase 2 SWIFT, presented at UEGW 2026 (statement of 19 October 2026): primary endpoint = clinical response at 12 weeks, 66% on 200 mg versus 37% on placebo; remission (secondary endpoint) 31% (18/59) versus 8% (5/60)
- OD-001 — Odyssey Therapeutics — open-label phase 2a, 56 evaluable patients: 27% clinical remission at week 12 among the 41 patients on 20 mg twice daily (UEG Week, 20 October 2026)
- ABBV-668 — Phase 2 trial in ulcerative colitis, 30 patients, completed 23 December 2024 (NCT05570006)
- Zasocitinib — Phase 2 placebo-controlled trial in ulcerative colitis, 213 patients, primary completion 14 July 2026 (NCT06254950)
- Zasocitinib — Open-label extension trial in Crohn's disease and ulcerative colitis, 192 patients (NCT06764615)
- Garutadustat — BETHESDA phase 2a placebo-controlled trial in ulcerative colitis (ISM5411), 80 patients, results expected August 2027 (NCT07265570)
- Tamuzimod — Phase 2 placebo-controlled trial in ulcerative colitis, 213 patients: « The Induction and Long-Term Extension Periods were completed and analyzed as planned » (NCT05156125)
- ALTB-268 — Phase 2 trial in ulcerative colitis refractory to biologics, 50 patients (NCT06109441)
- AZD7798 — AMALTHEA phase 2a trial in Crohn's disease, 120 patients, enrolment complete, trial completion announced for May 2027 (NCT06450197)
- Lutikizumab — Target CD phase 2 trial, risankizumab plus lutikizumab in Crohn's disease, 590 patients (NCT06548542)
- Lutikizumab — AbbVie ends development of lutikizumab as a monotherapy in ulcerative colitis: efficacy « numerically higher » than Humira but not sufficiently differentiated (announced 31 July 2025)
- Eltrekibart — Phase 2 trial in ulcerative colitis, combined with mirikizumab, 143 patients (NCT06598943)
- BI 3032950 — Phase 2 trial in ulcerative colitis, 80 patients, primary completion July 2027 (NCT06636656)
- Tirzepatide + Omvoh — Phase 3b trial in Crohn's disease with overweight or obesity, 290 patients, primary completion May 2028 (NCT06937099)
- Tirzepatide + Omvoh — Phase 3b trial in ulcerative colitis with overweight or obesity, 350 patients, primary completion April 2028 (NCT06937086)
- Anti-MAP vaccine — Phase 2 placebo-controlled trial (ISRCTN13731766), registry updated 8 September 2026: first enrolment due 1 September 2027, last 31 August 2028, completion 31 October 2030; ethics approval not yet submitted
- Anti-MAP vaccine — Phase 1 in 28 patients with active Crohn's disease (ISRCTN36126048), completed
- Anti-MAP vaccine — Phase 1 in 28 healthy volunteers (NCT03027193), Oxford, completed in 2020
- RHB-204 — RedHill Biopharma — positive FDA feedback on the path to approval of RHB-204 in Crohn's disease; trial funding still to be secured (2025)
- Bourgonje et al., blood signs before the diagnosis of IBD, Gut 2026
Download the image 1Download the image 2
